AFFiRiS AG: Encouraging Results from Phase I Studies of Two Alzheimer's Candidate Vaccines Trigger EUR 10 Mio. Milestone Payment
Tuesday, October 20, 2009 - 05:42
in Health & Medicine
Vienna, 20. October 2009: AFFiRiS AG today announced that the primary endpoints have been met for the Phase I clinical studies of its two Alzheimer's vaccines AD01 and AD02, which demonstrated favourable safety and tolerability profiles. These results trigger a 10 million EUR milestone payment from licensee GlaxoSmithKline Biologicals.